www.smithrx.comHealthcare / Digital HealthFounded: 2016Funding to Date: $104.84MM
With a focus on finding a better way to manage employee pharmacy benefits, SmithRx is a pharmacy benefit management (PBM) company that aims to use technology to connect employers and health plan members to specialized programs for pharmaceutical coverage. It provides a platform for small businesses so they can gain transparency and alternative methods to deliver pharmacy benefits. As a result, SmithRX strives to enable employees to access medications that are affordable and easy to acquire while also trying to reduce overhead costs for employers. SmithRx was was founded by Jake Frenz in 2016 and is headquartered in San Francisco, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
01/23/2024 | Series C | $60MM | $xx.xx | $354.68MM | Venrock | |
Price per Share
$xx.xx
Shares Outstanding
15,974,730
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Venrock
|
||||||
03/10/2022 | Series B-2 | $3.65MM | $xx.xx | $110.84MM | Founders Fund, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
14,799,896
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Founders Fund, Venrock
|
||||||
03/10/2022 | Series B-1 | $3.51MM | $xx.xx | $110.84MM | Founders Fund, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
3,339,298
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Founders Fund, Venrock
|
||||||
03/10/2022 | Series B | $20MM | $xx.xx | $110.84MM | Founders Fund, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
15,207,959
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Founders Fund, Venrock
|
||||||
07/31/2018 | Series A-2 | $5.56MM | $xx.xx | $51.57MM | Blumberg Capital, Box Group, Founders Fund, Nextgen Venture Partners, Precursor Ventures, Scifi Vc | |
Price per Share
$xx.xx
Shares Outstanding
3,117,204
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Blumberg Capital, Box Group, Founders Fund, Nextgen Venture Partners, Precursor Ventures, Scifi Vc
|
||||||
01/11/2018 | Series A | $9.05MM | $xx.xx | $33.26MM | Blumberg Capital, Box Group, Founders Fund, Nextgen Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
6,730,467
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Blumberg Capital, Box Group, Founders Fund, Nextgen Venture Partners
|
||||||
03/31/2017 | Series A-1 | $3.07MM | $xx.xx | $8.76MM | Blumberg Capital, Boxgroup, Four Cities Capital, Great Oaks Venture Capital, Nextgen Venture Partners, Precursor Ventures | |
Price per Share
$xx.xx
Shares Outstanding
3,160,387
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Blumberg Capital, Boxgroup, Four Cities Capital, Great Oaks Venture Capital, Nextgen Venture Partners, Precursor Ventures
|